CD8+ T cells of Tc2 phenotype mediate a GVL effect and prevent marrow rejection
- PMID: 9704464
- DOI: 10.1111/j.1423-0410.1998.tb05439.x
CD8+ T cells of Tc2 phenotype mediate a GVL effect and prevent marrow rejection
Abstract
Donor T cells mediate both beneficial and detrimental immune reactions in the setting of allogeneic BMT (alloBMT). T cells mediate the GVL effect and prevent marrow rejection, but also induce GVHD. In an attempt to favorably influence the balance of these allogeneic responses, we have evaluated the effect of donor CD4+, Th1/Th2 and CD8+, Tc1/Tc2 functional T cell subsets in murine marrow transplantation models. Our studies have identified the CD8+ Tc2 population (which is a cytolytic effector secreting the type II cytokines IL-4, IL-5, and IL-10) as a subset capable of mediating the GVL effect and preventing marrow rejection with reduced GVHD. We have also shown that the Tc2 subset can be generated in humans. These studies indicate that administration of donor CD8+ T cells of Tc2 phenotype represents a strategy for improving allo BMT outcome.
Similar articles
-
Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.Leuk Lymphoma. 2000 Jul;38(3-4):221-34. doi: 10.3109/10428190009087014. Leuk Lymphoma. 2000. PMID: 10830730 Review.
-
Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.Biol Blood Marrow Transplant. 1996 Oct;2(3):118-25. Biol Blood Marrow Transplant. 1996. PMID: 9199754
-
Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.Biol Blood Marrow Transplant. 2004 Sep;10(9):604-13. doi: 10.1016/j.bbmt.2004.06.006. Biol Blood Marrow Transplant. 2004. PMID: 15319772
-
Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.J Immunol. 1996 Dec 1;157(11):4811-21. J Immunol. 1996. PMID: 8943383
-
Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells.Semin Oncol. 2004 Feb;31(1):56-67. doi: 10.1053/j.seminoncol.2003.11.003. Semin Oncol. 2004. PMID: 14970938 Review.
Cited by
-
Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.Clin Cancer Res. 2011 Nov 1;17(21):6878-87. doi: 10.1158/1078-0432.CCR-11-1579. Epub 2011 Sep 26. Clin Cancer Res. 2011. PMID: 21948234 Free PMC article. Clinical Trial.
-
Memory CD4+ T cells do not induce graft-versus-host disease.J Clin Invest. 2003 Jul;112(1):101-8. doi: 10.1172/JCI17601. J Clin Invest. 2003. PMID: 12840064 Free PMC article.
-
Prevention of graft rejection by donor type II CD8(+) T cells (Tc2 cells) is not sufficient to improve engraftment in fetal transplantation.Fetal Diagn Ther. 2005 Jan-Feb;20(1):35-43. doi: 10.1159/000081367. Fetal Diagn Ther. 2005. PMID: 15608458 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials